Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.
Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.
A time-limited regimen including a PI3K inhibitor was safe and highly effective in patients with relapsed or refractory CLL.
BCL-2 protein hyperphosphorylation underlies both intrinsic and acquired resistance to venetoclax in CLL, study finds.
The GIVe regimen of obinutuzumab, ibrutinib, and venetoclax was a promising first-line, fixed-duration treatment for CLL.
Higher effector T-cell counts induced cytotoxic activity and more favorable responses to ibrutinib and rituximab in CLL.
Advertisement
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Mary Ann Anderson, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses the importance of World CLL Day.
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
All patients included in the study required treatment and had not previously received psychiatric treatment.
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Noteworthy regional disparities were noticed in treatment strategies.
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Dr. Brown shares what CLL news and session she's watching at the Eleventh Annual Meeting of SOHO.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.